Brief: Nls Pharmaceutics Announces Israeli Patent Grant Covering Mazindol For Treatment Of Attention Deficit Hyperactivity Disorder And Other Sleep Disorders Through 2037
20/12/2022 21:05
Dec 20 (Reuters) - NLS Pharmaceutics AG NLSP.O :
* NLS PHARMACEUTICS ANNOUNCES ISRAELI PATENT GRANT COVERING
MAZINDOL FOR TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY
DISORDER AND OTHER SLEEP DISORDERS THROUGH 2037
* NLS PHARMACEUTICS AG - POTENTIALLY FUNDED THROUGH 2025,
BEYOND
ANTICIPATED SUBMISSION OF NDA FOR MAZINDOL ER, EXPECTED IN LATE
2024 OR EARLY 2025
Further company coverage: NLSP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NewcelX AG
See all newsBrief: Newcelx Announces Pricing Of $1.4 Million Equity Financing At 20% Premium Pricing
Brief: Newcelx Submits Pre-IND Package To FDA For NCEL-101 For Treatment Of Type 1 Diabetes
Brief: Newcelx Updates Corporate Presentation To Highlight Type 1 Diabetes Flagship Program
U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences
U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing